These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 3140731

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Effect of calmodulin antagonists (W-5 and W-7) on antitumor activity of Tegafur and UFT (Tegafur plus uracil)].
    Kikuchi Y, Oomori K, Iwano I, Kizawa I, Miyauchi M, Kita T, Kato K.
    Nihon Sanka Fujinka Gakkai Zasshi; 1988 Apr; 40(4):422-8. PubMed ID: 3131462
    [Abstract] [Full Text] [Related]

  • 6. Hyperthermia enhances the inhibition of tumor growth by 1-(2-tetrahydrofuryl)-5-fluorouracil/uracil (1:4) in tumors in mice and humans.
    Emi Y, Kohnoe S, Yoshida M, Takahashi I, Maehara Y, Sugimachi K.
    Cancer; 1992 Sep 01; 70(5):1177-82. PubMed ID: 1515994
    [Abstract] [Full Text] [Related]

  • 7. [Effect of cepharanthine on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207)--5-fluorouracil delivery into tumor tissue].
    Ono M.
    Nihon Gan Chiryo Gakkai Shi; 1989 Jul 20; 24(7):1379-92. PubMed ID: 2509603
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. In vivo 19F NMR comparative study of 5-fluorouracil, 1-(2-tetrahydrofuryl)-5-fluorouracil (FT) and an FT-uracil coadministration system in mouse tumors.
    Kanazawa Y, Kurogi S, Shinohara S, Noda Y, Masuda K.
    Chem Pharm Bull (Tokyo); 1994 Apr 20; 42(4):774-8. PubMed ID: 8020119
    [Abstract] [Full Text] [Related]

  • 10. UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice.
    Yonekura K, Basaki Y, Chikahisa L, Okabe S, Hashimoto A, Miyadera K, Wierzba K, Yamada Y.
    Clin Cancer Res; 1999 Aug 20; 5(8):2185-91. PubMed ID: 10473104
    [Abstract] [Full Text] [Related]

  • 11. [Antineoplastic effect of UFT therapy (uracil-FT-207 combination therapy) on experimental pancreatic cancer transplanted in the pancreas and subcutaneous region].
    Ohyama K, Koike D, Odake Y, Takiyama Y, Saitoh T, Kagaya T, Takebe T, Ishii K.
    Gan To Kagaku Ryoho; 1982 Dec 20; 9(12):2168-74. PubMed ID: 6307180
    [Abstract] [Full Text] [Related]

  • 12. [5-FU concentration in blood and tissue of patients with renal cell carcinoma after administration of UFT].
    Masuda F, Suzuki M, Ohnishi T, Nakada J, Mori Y, Iizuka N, Machida T.
    Gan To Kagaku Ryoho; 1985 Feb 20; 12(2):320-4. PubMed ID: 3918507
    [Abstract] [Full Text] [Related]

  • 13. [Level of 5-FU in cancerous and normal tissues of nude mice after oral administration of tegafur coadministered with uracil (UFT)].
    Sekiguchi I, Suzuki M, Tamada T, Nishida M.
    Gan To Kagaku Ryoho; 1985 May 20; 12(5):1094-8. PubMed ID: 3922312
    [Abstract] [Full Text] [Related]

  • 14. [Experimental study of UFT in prostatic carcinoma (DU-145) in nude mice].
    Kagawa S, Takigawa H, Aga Y, Kurokawa K.
    Gan To Kagaku Ryoho; 1986 Dec 20; 13(12):3408-12. PubMed ID: 3098182
    [Abstract] [Full Text] [Related]

  • 15. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH, Pazdur R, Covington W, Brown N, Huo YY, Lassere Y, Kuritani J.
    Clin Cancer Res; 1998 Sep 20; 4(9):2085-8. PubMed ID: 9748123
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Immunotoxic effects of a new antineoplastic agent S-1 in mice--comparison with S-1, UFT and 5-FU].
    Kouchi Y, Maeda Y, Morinaga H, Ohuchida A.
    J Toxicol Sci; 1996 Nov 20; 21 Suppl 3():691-701. PubMed ID: 9021669
    [Abstract] [Full Text] [Related]

  • 18. [Effects of UFT on experimental liver metastases and on the immunologic capacity of the hosts].
    Tsuru S, Togami M, Taniguchi M, Nomoto K.
    Gan To Kagaku Ryoho; 1988 Jun 20; 15(6):1915-20. PubMed ID: 3132895
    [Abstract] [Full Text] [Related]

  • 19. Adjuvant effects of calmodulin antagonists on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (ftorafur) and a mixture of ftorafur and uracil (UFT) in nude mice bearing human ovarian carcinomas.
    Kikuchi Y, Oomori K, Iwano I, Kizawa I, Miyauchi M, Kita T, Kuki E.
    Gynecol Oncol; 1989 Nov 20; 35(2):172-6. PubMed ID: 2509301
    [Abstract] [Full Text] [Related]

  • 20. General pharmacological properties of UFT, a new type of anti-cancer agent consisting of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT) and uracil. I: Pharmacological analysis of the combined effect of FT and uracil.
    Yamamoto J, Toide K, Haruno A, Yoshimura Y, Unemi N.
    Arzneimittelforschung; 1981 Nov 20; 31(8):1268-78. PubMed ID: 6794578
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.